Literature DB >> 9743337

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

H M Finney1, A D Lawson, C R Bebbington, A N Weir.   

Abstract

Single chain Fv chimeric receptors, or T-bodies, are described with intracellular sequences comprising the costimulatory signaling domain of CD28 in series with the zeta-chain from the TCR complex. Using an engineered human single chain Fv derived from P67, an mAb with specificity for human CD33, and a spacer comprising an Ab hinge region with either Fcgamma or part of the CD28 extracellular region, fusion molecules were constructed to test the ability of single chain designs to mediate both primary signaling and costimulation from one extracellular binding event. Constructs with the CD28 signaling domain proximal and the zeta-chain distal to the membrane were found to express more efficiently in Jurkat than constructs with the opposite orientation and were capable of mediating up to 20 times more IL-2 production on stimulation with solid phase Ag when compared with transfectants expressing chimeric receptors with zeta-chain intracellular signaling domains only. IL-2 production was specific to Ag challenge and was completely inhibited by incubation with free Ab of the same specificity as the extracellular binding site of the construct, but not by an isotype-matched control Ab. The CD28 intracellular domain of these fusion proteins was shown to be capable of binding the p85 subunit of phosphatidylinositol 3'-kinase. These constructs represent the first of a new generation of single gene multidomain chimeric receptors capable of mediating both primary and costimulatory signaling specifically from a single extracellular recognition event.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9743337

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  176 in total

Review 1.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

Review 2.  Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.

Authors:  Lauren McLaughlin; C Russell Cruz; Catherine M Bollard
Journal:  Ther Adv Hematol       Date:  2015-12

Review 3.  Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.

Authors:  Diana C G Bouhassira; Joshua J Thompson; Marco L Davila
Journal:  Expert Opin Biol Ther       Date:  2015-02-09       Impact factor: 4.388

Review 4.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

5.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Imran G House; Junyun Lai; Amanda X Y Chen; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Izabela Todorovski; Emily Gruber; Madison J Kelly; Benjamin J Solomon; Stephin J Vervoort; Ricky W Johnstone; Ian A Parish; Paul J Neeson; Lev M Kats; Phillip K Darcy; Paul A Beavis
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Authors:  Thomas Shum; Robert L Kruse; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2018-05-14       Impact factor: 4.388

Review 9.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 10.  Paving the way towards universal treatment with allogenic T cells.

Authors:  Michelle H Townsend; Kelsey Bennion; Richard A Robison; Kim L O'Neill
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.